ASX CEO Connect LIVE Online | ASX CEO Connect has a proud tradition of bringing listed companies and investors together. | In partnership with nabtrade, ASX is delighted to host CEOs of leading mid to large-cap ASX-listed stocks who will present their business vision, strategy and latest achievements live to your device. | This virtual session, will include a market update from nabtrade followed by the company presentations. Registrants who join our live webinar will have the opportunity to submit questions via the webinar platform. | DATE | 12/04/2022 | TIME | 10:00am - 11:40am |
|
|
| |
| Can't attend? Don't worry, this webinar will be recorded and made available to all those who have registered to view on demand. | Kind regards ASX Events Team |
|
|
|
| | Telstra (ASX:TLS) | Vicky Brady, Chief Financial Officer Read more > |
|
| Telstra (ASX:TLS) is Australiaâs leading telecommunications and technology company, offering a full range of communications services and competing in all telecommunications markets. We believe itâs people who give purpose to our technology. That's why our purpose is to build a connected future so everyone can thrive. Thatâs why we build technology and content solutions that are simple and easy to use, including Australiaâs largest and fastest national mobile network. And thatâs why we strive to serve and know our customers better than anyone else â offering a choice of not just digital connection, but digital content as well. |
|
|
|
|
|
| Telix Pharmaceuticals (ASX:TLX) | Dr. Christian Behrenbruch, Chief Executive Officer & Managing Director Read more > |
|
| Telix is a biopharmaceutical company focused on the development and commercialisation of diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR). Telix is headquartered in Melbourne, Australia with international operations in Belgium, Japan, Switzerland and the United States. Telix is developing a portfolio of clinical-stage products that address significant unmet medical need in oncology and rare diseases. Telixâs lead product, gallium-68 (68Ga) gozetotide (also known as 68Ga PSMA-11) injection for prostate cancer imaging, has been approved by the U.S. Food and Drug Administration (FDA), and Australian Therapeutic Goods Administration (TGA), and we are also progressing marketing authorisation applications for this investigational candidate in Europe and Canada. |
|
|
|
|
|
| SiteMinder (ASX:SDR) | Sankar Narayan, Chief Executive Officer & Managing Director Read more > |
|
| SiteMinder (ASX:SDR) is the worldâs leading open hotel commerce platform, ranked among technology pioneers for opening up every hotelâs access to online commerce. Itâs this central role that has earned SiteMinder the trust of tens of thousands of hotels, across 150 countries, to sell, market, manage and grow their business. The global company, headquartered in Sydney with offices in Bangkok, Berlin, Dallas, Galway, London and Manila, generated more than 100 million reservations worth over US$35 billion in revenue for hotels in the last year prior to the start of the pandemic. |
|
|
|
|
|
| Vulcan Steel (ASX:VSL) | Rhys Jones, Chief Executive Officer & Managing Director Read more > |
|
| Founded in 1995, Vulcan Steel (ASX:VSL) is an Australasian-wide industrial product distributor and value-added processor with 29 logistics and processing facilities employing over 800 staff across the companyâs Steel and Metals divisions. Vulcan continuously strives to achieve best-in-class operational excellence in inventory management, processing capabilities, management of overheads and customer service. |
|
|
|
|
|
|
---|
|
|
| | Unsubscribe | Privacy Policy | This email was sent by: ASX Operations Pty Ltd. 20 Bridge Street, Sydney, NSW, 2000, Australia | Information and material to be presented at the seminar is for educational purposes only and does not constitute financial product or taxation advice. Investors should obtain independent advice before making investment decisions. No responsibility is accepted by ASX Limited ABN 98 008 624 691 and its related bodies corporate (“ASX”) for any loss arising in any way (including due to negligence) from anyone acting or refraining from acting as a result of information or material presented at the seminar. | © Copyright 2022 ASX Limited ABN 98 008 624 691. All rights reserved 2022. | https://click.marketing.asx.com.au/profile_center.aspx?qs=298e34feffed1011d29df52c896272327310f7633528f697cdd7287e367c0e32e8bbc4fba959e902ecf66d59e0c043d7 |
|
|
|
| | | | | | | | | | | | | | | | | | | | | | | | |
|
|
|